BioCentury
ARTICLE | Clinical News

Yondelis trabectedin: Phase II interim data

June 14, 2004 7:00 AM UTC

PharmaMar S.A., Madrid, Spain Product: Yondelis trabectedin Business: Cancer Molecular target: DNA Description: Cytotoxic alkaloid derived from a marine organism that binds the minor groove of DNA I...